Company* (Country; Symbol)

University/ Nonprofit@

Type Of Agreement

Product Area

Details (Date)

Accentia Inc.*

Mayo Foundation for Medical Education and Research

License agreement

Accentia will develop and commercialize Mayo's method for treating chronic sinusitis

The royalty-bearing license for the U.S. and Europe covers a low-dose, topical formulation of amphotericin B (4/13)

Aegis Therapeutics Inc.*

University of Alabama at Birmingham

License agreement

Aegis licensed technology for noninvasive delivery of peptide and non-peptide drugs

Aegis has exclusive rights to further develop and commercialize the Intravail technology; terms were not disclosed (4/12)


Tumor Biology Center Freiburg (Germany)


To jointly validate known angiogenesis drugs for cancer, heart diseases and eye diseases

The drugs were identified using TBCF's Spherogenex screening platform; AngioGenetics acquired rights to those results (5/12)

Ardais Corp.*

Duke University Medical Center

Supply agreement

Ardais will create a biorepository providing human biomaterials and clinical data for Duke's cancer research

The deal expands on an existing alliance, and could move beyond cancer; terms were not disclosed (4/19)

Astex Technology
(UK) (all in the UK)

The Institute of Cancer Research, the Wellcome Trust and Cancer Research Technology


To discover drugs against the cancer target BRAF been ongoing among the three

Astex will contribute expertise in fragment- based discovery to the collaboration, which already had research centers (3/22)

BioE Inc.*

University of Southern California


To support development of non-embryonic stem cell therapies for neuro- degenerative diseases

BioE will provide stem cells derived from umbilical cord blood and related support; terms were not disclosed (3/23)


Southern Research Institute

Extended option agreement

To manufacture, market and distribute clofarabine to treat pediatric and adult acute leukemias in Japan and Southeast Asia

The two parties are actively seeking a co- marketing partner to convert the option into a license on terms to be agreed upon by Bioenvision and SRI (5/18)

BioLineRx Ltd. (Israel)

Tel Aviv University and Bar-Ilan University (both in Israel)

License agreement

BioLineRx licensed compounds targeting schizophrenia and other neurological disorders

Terms of the exclusive worlwide license were not disclosed; the compound class was not identified (5/5)

Bionomics Ltd. (Australia; ASX:BNO)

Southern Cross University (Australia)


To discover drugs targeting epilepsy and anxiety

Bionomics will screen natural products from the university's collection for activity against biological targets (3/29)

BTG plc* (UK)

Cancer Research Technology Ltd. (UK)


BTG obtained exclusive worldwide rights to a series of quinazoline antitumor agents

BTG will be responsible for the development and commercialization of the compounds (5/19)

BTG plc* (UK)

King's College London (UK)

Technology acquisition

BTG acquired drug discovery programs in the areas of diabetes and neurodegeneration

BGC20-0402 is an inhibitor of CORE-2 GlcNAc- transferase, applicable in diabetic retinopathy; the other program is in preventing iron-induced neurotoxicity (5/4)

Cangene Corp. (Canada; TSE:CNJ)

Defence R&D Canada


One project, with the University of British Columbia, will be to identify structural information about anthrax

The second project is to use Cangene's expertise in antibodies to investigate potential treatments for smallpox exposure; terms were not disclosed (4/28)


Naval Medical Research Center

Collaborative Research and Development Agreement

To jointly evaluate CEL- 1000 with new adjuvants against malaria-causing Plasmodium

Tests will start in mice and could move on to primates; terms were not disclosed (4/28)

Chemical Diversity Labs Inc.*

Brigham and Women's Hospital


To discover new tools for understanding and treating neuro-degenerative diseases

CDL will design and supply a small-molecule discovery library for screening by the Laboratory for Drug Discovery in Neuro-degeneration (4/6)

CombiMatrix Group (unit of Acacia Research Corp.; CMBX)

Oklahoma State University


To characterize influenza A viruses at the genomic level

University researchers will use CombiMatrix's Bird Flu Custom-Array devices in the work; terms were not disclosed (3/26)

CombiMatrix Group (unit of Acacia Research Corp.; CMBX)

Retrovirology Laboratory irsiCaixa (Spain)

Expanded collaboration

To conduct initial efficacy screening of siRNA compounds against hepatitis C virus

The parties will continue their work in the area of HIV; terms were not disclosed (3/23)

Cognia Corp.*

Harvard Medical School, Yale Medical School and SUNY Binghamton

License agreements

The universities licensed the Cognia Molecular information-management system

Terms were not disclosed (4/22)

Crucell NV (the Netherlands; CRXL)

Aeras GlobalTB Vaccine Foundation


Deal focused on improving the Bacillus Calmette-Guérin vaccine using Crucell's PER.C6 and AdVac technologies

Crucell can earn up to $2.9M by reaching development milestones in the project, which aims to improve the only approved TB vaccine (3/24)

Debiopharm SA* (Switzerland)

Shanghai Institute of Materia Medica (China)

License agreement

Debiopharm exercised its option to license ZT-1, a cholinesterase inhibitor for treating Alzheimer's disease

Debiopharm has exclusive worldwide rights to develop and commercialize ZT-1, except in China; SIMM will supply the huperzine A derivative for the product (5/12)

Echelon Biosciences Inc.*

University of Texas M. D. Anderson Cancer Center


To advance cell- signaling compounds in cancer through preclinical testing

M.D. Anderson will conduct trials of resulting candidates; Echelon has an option to issue the center a warrant for stock in exchange for commercialization rights (4/19)

Entercel Ltd.* (formed by Emergent Technologies Inc.)

University of Texas at Austin

License agreement

Entercel licensed a chemical-based platform that adjusts a cell's ability to resist foreign compounds

Emergent formed Entercel Ltd. to commercialize the technology, which is expected to have applications in agriculture (4/29)

Emergent Technologies Inc.*

Texas Tech University Health Sciences Center

License agreement

Emergent licensed antibody drug discovery technology

ETI formed Receptor Logic Ltd. to commercialize the technology, which will be used to design customized treatments for cancer and infectious diseases (3/26)

Entelos Inc.*

Massachusetts Institute of Technology


To build in silico models for immunology research

Entelos will provide MIT with a biological modeling platform for work focused on the breakdown of intracellular signaling (3/30)

Enzo Biochem Inc. (NYSE:ENZ)

University of Connecticut Health Center

License and development agreement

To develop therapeutics for the stimulation and enhancement of bone formation

Enzo gets an exclusive license to the technology, which relates to modulating signaling pathways in cell development and differentiation (4/21)

EraGen Biosciences Inc.*

Emory University


To develop a geno-typing system for early detection of HIV variants

EraGen will provide genotyping systems for HIV, and Emory will provide expertise and testing results (3/22)

Eurand International SpA* (Italy)

University of Urbino Biotechnology Centre (Italy)

Research agreement

To evaluate a cancer compound derived from indol-3-carbinol, which is present in cruciferous vegetables

Eurand has an option for exclusive worldwide rights; it would fund development and pay milestones and royalties to the university (4/14)

Genaissance Pharmaceuticals Inc. (GNSC)

University of Utah and Yale University

Amended license agreement

They simplified terms on the royalty rate on genetic tests and extended Genaissance's rights under the deal

The license involves patents related to five cardiac ion channel genes originally licensed by DNA Sciences Inc. in March 2003 (4/29)

Genaissance Pharmaceuticals Inc. (GNSC)

University of Rochester and the Mayo Foundation for Medical Education and Research

Access agreements

Genaissance gets access to clinical expertise, research samples and disease-associated mutations for developing tests for cardiac conditions

The first product is expected to be a genetic test for cardiac ion channel mutations; terms of the agreements were not disclosed (4/6)

GenoMed Inc. (Pink sheets:GMED)

McGill University and Genome Quebec Innovation Centre (Canada)

Service agreement

The Genome center will perform large-scale screening projects for GenoMed

GenoMed's genotyping consists of two stages: screening a number of single nucleotide polymorphisms and validating a smaller number of them (5/19)

Genomics Collaborative Inc.*

Whitehead Institute for Biomedical Research


Partnership to study the human Y chromosome's role in male infertility

They will start with a pilot study of DNA samples from 4,000 U.S. males, and expand the work if that proves successful (3/22)

Geron Corp. (GERN)

American Type Culture Collection

License agreement

ATCC got a license to create and distribute cell lines immortalized with human telomerase reverse transcriptase

The nonexclusive license, which includes the hTERT gene itself, covers only the market for research use (4/10)

Gilead Sciences Inc. (GILD)

Southern ResearchInstitute


The institute will do early chemistry and screening work for Gilead

The deal extends an earlier contract and involves support for Gilead's drug discovery efforts; terms were not disclosed (4/19)

GTC Biotherapeutics Inc. (GTCB)

Mayo Clinic


Mayo will conduct preclinical tests of GTC's antibody to CD137 for cancer applications

Work on the agonistic antibody is being funded by a National Institutes of Health grant (5/4)

Hard to Treat Diseases Inc. (OTC BB:HTDS)

University of Colorado and the Denver Veteran's Affairs Medical Center

Material transfer agreement and a sponsored R&D agreement

They will study the effect of the immunostimulant Tubercin on a variety of diseases

The deal has a two-year term, and was made with the university's Health Science Centers; terms were not disclosed (5/3)

Health Discovery Corp. (OTC BB: HDVY)

University of Miami


Deal to use Health Discovery's Fractal Genomics Modeling to identify new patterns of biomarkers

The focus is on AIDS- related dementia; any discoveries from the effort would be jointly owned (3/23)

Health Discovery Corp. (OTC BB: HDVY)

Stanford University


Deal to use Health Discovery's Fractal Genomics Modeling to identify new patterns of biomarkers

The focus is on lymphatic insufficiency; any products developed using the technology would be jointly owned (3/22)


The Center for the Advancement of Genomics


To advance medical and genomic discoveries

They will combine their expertise to design new solutions in genome sequencing and other areas (3/31)

Intercell AG* (Austria)

Statens Serum Institut (Denmark)

License agreement

For development of a prophylactic tuberculosis vaccine

The vaccine combines TB antigens developed by SSI with Intercell's synthetic immunizer IC 31 as adjuvant; Intercell gets up- front and milestone payments, and would share in any profits (3/17)

Invitrogen Corp. (IVGN)

National Human Genome Research Institute and the National Cancer Institute

Access agreement

The institutes gained access to Invitrogen's Gateway and Super-Script technologies

The institutes will use the technology with their Mammalian Gene Collection Program and be able to deliver resulting clones to the academic community (5/4)

Lorus Therapeutics Inc. (Canada; TSE:LOR)

University of Toronto


The university will help with development and delivery strategies for Lorus compounds

The newly discovered, low- molecular-weight compounds have shown anticancer and antibacterial properties; the work will be funded in part through a grant (5/12)

Lynx Therapeutics Inc. (LYNX)

National Cancer Institute and various institutions


Lynx will apply its Massively Parallel Signature Sequencing technology to characterize genomic changes in cancer

Lynx will receive payments for the DNA-sequencing services; Lynx also signed new deals with the National Institute of Environmental and Health Sciences and the Howard Hughes Medical Institute, and extended deals with the Ludwig Institute for Cancer Research and the National Institute on Aging (5/13)

Millennium Pharmaceuticals Inc. (MLNM)

National Cancer Institute

Cooperative Research and Development Agreement

To study the link bet- ween angiotensin-con- verting enzyme 2 and the SARS virus

The NCI will conduct cell-based studies to identify the structure of the ACE2/SARS complex; Millennium has an option to license resulting discoveries (4/1)

Myriad Genetics Inc. (MYGN)

Not disclosed

License agreement

Myriad licensed U.S. rights to detect mutations in the Mut Y Homolog gene

Myriad intends to add the test to its Colaris product line for detecting hereditary colon cancer; terms were not disclosed (4/14)

NeoRx Corp. (NERX)

The University of Missouri

Manufacturing and supply agreement

The university will supply the radioisotope holmium-166 for Phase III trials of NeoRx's STR

The university's Columbia Res- earch Reactor Center will supply the product for trials in cancer under undisclosed terms (3/22)

Norak Biosciences Inc.*

Development Center for Biotechnology (Taiwan)

Nonexclusive license agreement

DCB got certain rights to use Transfluor technology for screening GPCRs

DCB is a government-funded, nonprofit research organization; terms of the deal were not disclosed (4/6)

Nuevolution A/S* (Denmark)

Scripps Research Institute

License agreement

Nuevolution got rights to patents related to generating and screening bi-functional molecules

The molecular evolution technology will be used to generate millions of drug-like molecules; terms were not disclosed (5/13)

OriGene Technologies Inc.*

The Translational Genomics Research Institute

Technology acquisition

The institute acquired the TrueClone Collection of human cDNA clones

The clones will be used in high- throughput drug target discovery and development (5/5)

OriGene Technologies Inc.*

Riken Protein Research Group (Japan)

Technology acquisition

Riken acquired the TrueClone Collection of 20,000 full-length human cDNA clones

The clones will be used in structural proteomics and related protein functional analysis programs (3/30)

Panacea Pharmaceuticals Inc.*

Universty of Texas M.D. Anderson Cancer Center


To further explore the biology of human aspartyl beta-hydroxylase regulation and expression in lung carcinomas

The collaboration also will explore the efficacy of compounds aimed at inhibiting HAAH activity; HAAH rights are owned by Panacea (5/3)

ParAllele BioScience Inc.*

National Cancer Institute

Early access agreement

The NCI will use the company's MegAllele SNP genotyping platform

Terms were not disclosed (5/12)

Peregrine Pharmaceuticals Inc. (PPHM)

The Foundation Fighting Blindness


The foundation will conduct preclinical studies of Vascular Targeting Agent technology for eye diseases

The technology will be tested in angiogenesis-dependent conditions; terms were not disclosed (4/28)

Prolexys Pharmaceuticals Inc.*

Arizona State University

Research collaboration

To discover peptides and small molecules that modulate vascular tone and can treat conditions associated with vaso- spasm and vasoconstriction

Prolexys will assist in characterizing and isolating protein interactors involved in a pathway discovered at ASU's Arizona Biodesign Institute; terms of the deal were not disclosed (4/6)

Protagen AG* (Germany)

German Resource Center for Genome Research (RZPD)

License agreement

Protagen provided RZPD its UNIclone technology for creating non-redundant gene libraries

Up to 12 more libraries from human, rat and murine tissues will be created under the deal; they also will offer contract manufacturing of recombinant proteins (4/5)

Samaritan Pharmaceuticals Inc. (OTC BB:SPHC)

Georgetown University

License agreement

Samaritan got licenses to develop and sell drug candidates for treating HIV resistance

Samaritan got exclusive world- wide rights in exchange for royalties and payments if the drugs are partnered (5/13)

Seattle Genetics Inc. (SGEN)

Imperial College Innovations Ltd.

License agreement

For exclusive rights to a monoclonal antibody targeting a cell-surface, tumor-associated antigen

The company plans to evaluate the therapeutic potential of the antibody against a variety of cancers, including hematologic malignancies and solid tumors, such as breast, colon and bladder cancer; Seattle Genetics has development, manufacturing and worldwide commercialization rights, and Imperial College will receive an up-front fee, milestone payments and potential royalties (5/19)

Senetek plc (SNTK)

Unnamed research foundation

Agreement extension

Senetek's license covers manufacturing and sales of monoclonal antibodies used in disease research

The license for three cell lines was extended from July 2004 through September 2005; the foundation gets an extension fee and royalties on sales (5/12)

Targeted Molecular Diagnostics LLC*

Johns Hopkins University and the Weizmann Institute of Science (Israel)


To identify the role of the Epigen ligand in the clinical behavior of prostate cancer

The goal is to develop markers for prostate cancer; terms were not disclosed (3/22)

Tm Bioscience Corp. (Canada; TSE:TMC)

University of Louisville Medical School

Supply agreement

Tm is providing its Tag-It P450-2D6 Mutation Detection Kit

Kits covered under the two-year contract identify mutations com- mon in patients with atypical drug metabolism (4/29)

Toxin Alert Inc. (Canada; TSE:TOX)

Mississippi State University

Development agreement

To develop large-scale antibody production from plants

The parties will seek U.S. funding of $2M per year for the work; Toxin Alert would use the anti- bodies for detecting pathogens in food (4/12)

Viragen Inc. (AMEX:VRA)

University of Miami

Agreement extension

Deal covers a novel form of an immune-enhancing drug (IEP 11) that has shown activity in cancer

Viragen continues to have an option to acquire exclusive worldwide rights to the small peptide molecule (5/12)


This chart does not include grants or contract awards, or agreements between biotech companies and clinical trial centers.

* Denotes privately held company.

@ Some institutions listed have for-profit components. They are located in the U.S. unless otherwise noted.

Unless otherwise noted, shares are traded on the Nasdaq exchange.

AMEX = American Stock Exchange; ASX = Australian Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange.